Skip to main content

Libtayo 350 mg/7 mL (50 mg/mL) injection Images

Generic Name: cemiplimab

This medication has been identified as Libtayo 350 mg/7 mL (50 mg/mL) injection. It is supplied by Regeneron Pharmaceuticals, Inc.

Libtayo is used in the treatment of Squamous Cell Carcinoma; Basal Cell Carcinoma; Non-Small Cell Lung Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Libtayo 350 mg/7 mL (50 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Libtayo 350 mg/7 mL (50 mg/mL) injection medicine

Libtayo

Generic Name
cemiplimab
Strength
350 mg/7 mL (50 mg/mL) injection
Availability
Prescription only
Drug Class
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
CSA Schedule
Not a controlled drug
Labeler / Supplier
Regeneron Pharmaceuticals, Inc.
National Drug Code (NDC)
61755-0008

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.